Reports Q3 revenue $62.8M, consensus $62.72M. “We are proud to have simultaneously published in the New England Journal of Medicine and presented at ESMO 2023 the unprecedented three-year survival follow-up from our pivotal trial of KIMMTRAK in metastatic uveal melanoma,” said Bahija Jallal, Immunocore’s Chief Executive Officer. “We continue to pioneer TCRs by exploring KIMMTRAK in the adjuvant setting with the EORTC-sponsored ATOM Phase 3 clinical trial and progressing the PRAME franchise in multiple solid tumors.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMCR:
- Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
- Roku upgraded, Amazon initiated: Wall Street’s top analyst calls
- Immunocore initiated with an Overweight at Cantor Fitzgerald
- Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
- Immunocore initiated with Outperform on TCR leadership at Baird
